Panama City

Researchers are investigating new treatment options for people with advanced solid tumors, which are cancers that have spread to other parts of the body and often resist current therapies. This study focuses on evaluating the safety, tolerability, how the body processes, and effectiveness of Mocertatug Rezetecan Mo-Rez when combined with other anti-cancer medicines for participants who have not responded to standard treatments, cannot tolerate them, or have no effective options available. The study is a Phase 12 randomized, multi-cohort clinical trial sponsored by GlaxoSmithKline. Participants will receive Mo-Rez given through an intravenous IV infusion alone or combined with other cancer drugs such as Dostarlimab or Bevacizumab, depending on their specific type of cancer and study group. The study has two main modules one focusing on endometrial cancer treated with Mo-Rez plus Dostarlimab, and another for ovarian cancer treated with Mo-Rez with or without Bevacizumab. Treatment cycles and dosing schedules will be followed as per study protocols, with ongoing monitoring throughout the treatment period. During the trial, participants will undergo regular assessments including scans to measure tumor response, laboratory tests, vital sign monitoring, and evaluations of side effects. Researchers will track dose limiting toxicities, adverse events, and clinical activity such as tumor response rates over several months. Blood samples will be collected to study how Mo-Rez is processed in the body and to monitor immune responses. The study will last until the completion date in 2028, with participants monitored regularly to assess safety and treatment effects.

Researchers are evaluating a new medicine called Risvutatug Rezetecan also known as GSK5764227 or Ris-Rez in people worldwide who have advanced gastrointestinal cancers that cannot be removed by surgery. These participants have previously received treatment for their cancer. The study aims to understand how well this medicine works, how safe it is, and how the body processes it. Participants will receive Risvutatug Rezetecan alone or combined with other drugs, including Drug 1, Drug 2, Drug 3, and Drug 4. The study includes different dosing groups and combinations to assess the medicines effects. Treatments will be given according to the assigned group, and the study follows a randomized design without masking. During the trial, participants will undergo regular assessments including scans and laboratory tests to monitor cancer response and safety. Researchers will measure outcomes such as tumor response rate, duration of response, progression-free survival, and changes in vital signs and blood tests. The study will also track side effects and how the medicine is processed by the body over up to approximately 37 months. Participants will be closely monitored throughout the study period, which lasts several years.

Researchers are comparing two bowel preparation agents, Lactulose and Sodium Phosphate, to determine which is better for high-quality colonoscopies. This trial is conducted as a randomized, double-blind study involving patients scheduled for outpatient colonoscopy at hospitals in Mexico and Panama between April 1, 2025, and November 30, 2025. The study focuses on colonoscopy quality, patient tolerance, satisfaction, and changes in electrolyte levels. Participants will be randomly assigned to receive either Lactulose or Sodium Phosphate as their bowel preparation on the day they receive their colonoscopy appointment. Both agents are given orally before the procedure. The study excludes patients undergoing emergency or therapeutic colonoscopies and those with specific medical conditions or pregnancy. Data collected include bowel preparation effects and colonoscopy findings, analyzed using statistical software. During the study, participants will undergo assessments such as blood tests to monitor electrolyte changes, evaluation of gastrointestinal side effects, and measures of bowel preparation quality using the Boston Bowel Preparation Scale. Researchers will also assess palatability and adenoma detection rates. Participant data will be securely stored and analyzed to draw conclusions on the best preparation method. The total study period runs from April to November 2025.

Researchers are evaluating the efficacy of perioperative dostarlimab compared with the standard of care in participants with untreated T4N0 or Stage III resectable colon cancer that shows defective mismatch repair or high microsatellite instability dMMRMSI-H. This phase 3, open-label, randomized study focuses on these specific colon cancer patients to assess if dostarlimab can improve outcomes compared to current treatments. Participants are randomly assigned to receive either dostarlimab before and after surgery or the standard of care treatments, which include FOLFOX or CAPEOX chemotherapy or post-surgery observation. Dostarlimab is given as monotherapy during the perioperative period. The study carefully monitors participants for up to approximately 5 years to evaluate long-term effects. During the trial, participants undergo regular assessments including event-free survival reviewed by blinded independent central review, overall survival, and pathological response evaluations. Safety is closely monitored by tracking adverse events, immune-related effects, and serum concentrations of dostarlimab across treatment cycles. The study involves frequent follow-ups to understand treatment impact and ensure participant well-being throughout the extended observation period.